Photorefractive keratectomy in treatment of refractive amblyopia in the adult population

Çağıl, Nurullah; Uğurlu, Nagihan; Çakmak, Hasan Basri; Kocamış, Sücattin İlker; Turak, Dervis; Şimşek, Şaban

doi:10.1016/j.jcrs.2011.06.026

Cited by 16 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The localization and adhesion of the embryo to the epithelial cells is the first step in the initiation of implantation. Suboptimal embryo adhesion is widely thought to be a major cause of implantation failure 25 , 26 . Studies have shown that many factors are involved in regulating embryo adhesion processes.…”

Section: Discussionmentioning

confidence: 99%

Increased Krüppel-like factor 12 impairs embryo attachment via downregulation of leukemia inhibitory factor in women with recurrent implantation failure

et al. 2018

View full text Add to dashboard Cite

Recurrent implantation failure (RIF) caused by various etiological factors remains a challenge for fertility clinicians using assisted reproductive technology (ART) worldwide. Dysregulation of leukemia inhibitory factor (LIF) in the endometria of women with RIF is involved in impaired endometrial receptivity and embryo adhesion. However, the mechanism through which LIF expression is regulated in women with RIF is still poorly understood. Our previous study noted that the abnormally increased endometrial Krüppel-like factor 12 (KLF12) in RIF women led to impaired decidualization and embryo implantation. Here, we further found that KLF12 inhibited embryo adhesion in vivo and in vitro by repressing LIF expression. Mechanistically, KLF12 bound to conserved sites (CAGTGGG, −6771 to −6765 and −7115 to −7109) within the LIF promoter region and repressed LIF transcription directly. Exogenous LIF significantly reversed the KLF12-mediated repression of BeWo spheroid adhesion. KLF12 expression was reduced significantly in Ishikawa cells treated with progestogen, which was due to the activation of Akt signaling. These findings may provide novel potential therapeutic regimens for patients with RIF and disrupted endometrial receptivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Krüppel-like factor 12 impairs embryo attachment via downregulation of leukemia inhibitory factor in women with recurrent implantation failure

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The exact mechanism of the increase in CDVA is unclear, but the reason for the improvement may be the relative magnification of the image after an anterior chamber pIOL implantation when compared with spectacle lenses [ 14 ]. There is agreement in the literature that improvement occurs in CDVA after corneal refractive surgery or pIOL implantation [ 15 – 17 ].…”

Section: Discussionmentioning

confidence: 98%

Verisyse versus Veriflex Phakic Intraocular Lenses: Refractive Outcomes and Endothelial Cell Density 5 Years after Surgery

Yaşa

Ağca

2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To compare refractive stability, central endothelial cell density (ECD), and complications between Verisyse (Abbott Medical Optics, Netherlands) and Veriflex (Abbott Medical Optics, Netherlands) phakic intraocular lenses (pIOL) over five years. Methods We retrospectively reviewed the medical records of patients who underwent Verisyse or Veriflex pIOL implantation for surgical correction of myopia. Patients with a 5-year follow-up period were included in the study. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), spherical equivalent of manifest refraction (SE), and ECD were compared between the groups preoperatively and 1, 3, and 5 years postoperatively. Results The study included 47 eyes in the Verisyse group and 50 eyes in the Veriflex group. There was no significant difference in mean SE, UDVA, CDVA, and ECD preoperatively or postoperatively. In both groups, there was a statistically significant myopic shift between 1-year and 5-year visits (−0.25 ± 0.30 D and −0.23 ± 0.48 D in the Verisyse and Veriflex groups, respectively). There was no significant difference between the groups in terms of efficacy and safety indexes at 5 years. ECD loss was highest during the first year (3.9% loss in the Verisyse group and 3.9% loss in the Veriflex group, p=0.670). At 5 years, the mean cumulative ECD losses in the Verisyse and Veriflex groups were 7.42% and 7.64%, respectively (p=0.709). Cataracts developed in 2.1% of the eyes in the Verisyse group and in 2.0% of those in the Veriflex group. No sight-threatening complications were observed. Conclusion Verisyse and Veriflex pIOLs are highly effective for treating high myopia up to 5 years after surgery. Longitudinal studies with longer follow-up periods are necessary to determine the endothelial safety profile.

show abstract

“…Although the exact mechanism is unclear, the relative magnification of the image and the reduction in visual aberrations after an anterior chamber pIOL implantation when compared to spectacle lenses may be the reason for the improvement [ 20 ]. In addition, the studies in the literature that evaluate CDVA improvement in adult amblyopic eyes after laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), or pIOL implantation agree that improvement occurs; however, the rates vary over a wide range [ 19 , 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia

Yaşa

Ürdem

Ağca

et al. 2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To report clinical results of a foldable, hydrophilic acrylic, single-piece, injectable, posterior chamber phakic intraocular lens (pIOL). Material and Methods Medical records of patients who underwent posterior chamber phakic IOL (Eyecryl Phakic IOL, Biotech Vision Care, Ahmedabad, India) implantation for surgical correction of myopia were retrospectively reviewed. Only patients with at least a one-year follow-up were included. Manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell density (ECD), and pIOL vault were analyzed at 1, 3, 6, and 12 months after surgery. Complications observed during and after surgery were also recorded. Results The study included 58 eyes of 29 patients. Mean patient age was 32 ± 7 years. Spherical equivalent of manifest refraction was −13.41 ± 3.23 D preoperatively and −0.44 ± 0.55 D postoperatively. Preoperative CDVA was 0.29 ± 0.71 logMAR. Postoperative UDVA and CDVA were 0.21 ± 0.66 and 0.15 ± 0.69 logMAR, respectively, at the 12-month visit. At the 12-month visit, the efficacy index was 1.20 and the safety index was 1.39. Mean ECD was 2713 ± 339 cells/mm2 at the preoperative visit and 2608 ± 362 cells/mm2 at the 12-month visit (3.9% loss, p < 0.001). ECD loss from 3 months to 12 months was not statistically significant. No significant cataract formation, significant endothelial cell loss, glaucoma, uveitis, or any other vision-threatening complication was observed. Conclusion Based on postoperative experience, we have found that Eyecryl Phakic IOL is safe and effective for treating high myopia.

show abstract

Photorefractive keratectomy in treatment of refractive amblyopia in the adult population

Abstract: After PRK to eliminate and correct refractive errors in anisometropic amblyopia, visual acuity improved significantly in 70% of adult patients with no previous occlusion or chemical penalization treatment.

Cited by 16 publications

References 32 publications

Increased Krüppel-like factor 12 impairs embryo attachment via downregulation of leukemia inhibitory factor in women with recurrent implantation failure

Increased Krüppel-like factor 12 impairs embryo attachment via downregulation of leukemia inhibitory factor in women with recurrent implantation failure

Verisyse versus Veriflex Phakic Intraocular Lenses: Refractive Outcomes and Endothelial Cell Density 5 Years after Surgery

Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia

Contact Info

Product

Resources

About